← XTL BIOPHARMACEUTICALS LTD

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Net Income — — — — — — ($1.3m) ($1.8m) ($1.0m) ($7.0m)
Net Income From Continuing Operations — — — — — — ($1.3m) ($1.8m) ($1.0m) ($7.0m)
Depreciation and amortization — — — — $1k $1k $1k $0 $199k $0
Depreciation Amortization Depletion — — — — — — $1k $0 $199k $0
Deferred Income Tax — — — — — — $0 $0 ($130k) $0
Deferred Tax — — — — — — $0 $0 ($130k) $0
Adjustments For Share-Based Payments $127k $39k $22k $5k $51k $37k $14k $3k $264k —
Share-based payment expense — — — — $51k $37k $14k $3k $264k $346k
Asset Impairment Charge — — — — — — — $0 $0 $531k
Additional Financial Items
Adjustments For Decrease Increase In Trade Account Receivable — — — — — — — — $39k —
Adjustments For Finance Costs — — — — — — — $27k $14k —
Adjustments For Increase Decrease In Trade Account Payable ($101k) ($13k) ($47k) ($21k) $22k ($23k) ($44k) $19k $208k —
General and Administrative Expense $1.3m $1.2m $755k $807k $910k $1.0m $850k $734k $1.6m —
Goodwill — — — — — — — — $3.2m —
Interest Received Classified As Operating Activities — ($4k) ($87k) ($93k) ($33k) — — — — —
Purchase Of Intangible Assets Classified As Investing Activities $64k — — — — — — — — —
Repayments Of Borrowings Classified As Financing Activities — — — — — — — — $13k —
Net Loss for the Year — ($781k) $3.0m ($1.3m) ($782k) $435k ($1.3m) ($1.8m) ($1.0m) ($7.0m)
Purchase of fixed assets — — — ($2k) ($1k) — — — ($54k) —
Interest from bank deposit — $4k $74k $93k $33k $8k $36k $41k $34k —
Issuance of shares and warrants — — — — — $385k — — $1.5m —
Revaluation of marketable securities — — ($2.8m) $574k ($138k) ($747k) $1.5m $1.0m ($167k) ($5k)
Revaluation of warrants — ($765k) ($974k) ($584k) $2.2m ($719k) ($1.1m) — ($926k) ($1.1m)
Interest income — — ($87k) ($93k) ($33k) ($8k) ($36k) ($41k) ($34k) ($60k)
Decrease (increase) in prepaid expenses and other current assets — — — — — ($31k) $25k $45k ($58k) $28k
Decrease in trade receivables — — — — — — — — $39k $157k
Increase (decrease) in accounts payable — ($157k) ($47k) ($21k) $22k ($23k) ($44k) $19k $208k ($187k)
Net operating asset and liability — — — — — — — $64k $189k ($2k)
Beginning Cash Position — — — — — — $3.0m $2.1m $1.4m $371k
Cash Flow From Continuing Financing Activities — — — — — — $0 $0 $1.4m $208k
Cash Flow From Continuing Investing Activities — — — — — — $36k $41k ($844k) $522k
Change In Account Payable — — — — — — ($44k) $19k $208k ($187k)
Change In Payable — — — — — — ($44k) $19k $208k ($187k)
Change In Payables And Accrued Expense — — — — — — ($44k) $19k $208k ($187k)
Change In Prepaid Assets — — — — — — $25k $45k ($58k) $28k
Change In Receivables — — — — — — $0 $0 $39k $157k
Change In Working Capital — — — — — — ($19k) $64k $189k ($2k)
Changes In Account Receivables — — — — — — $0 $0 $39k $157k
Changes In Cash — — — — — — ($865k) ($666k) ($1.0m) ($295k)
End Cash Position — — — — — — $2.1m $1.4m $371k $76k
Financing Cash Flow — — — — — — $0 $0 $1.4m $208k
Free Cash Flow — — — — — — ($901k) ($707k) ($1.7m) ($1.0m)
Gain Loss On Investment Securities — — — — — ($719k) ($1.1m) — ($926k) ($1.1m)
Gain Loss On Sale Of Business — — — — — — — $0 $0 $6.2m
Interest Received CFI — — — — — — $36k $41k $34k $0
Investing Cash Flow — — — — — — $36k $41k ($844k) $522k
Issuance Of Capital Stock — — — — — — $0 $0 $1.5m $0
Net Business Purchase And Sale — — — — — — $0 $0 ($410k) ($5k)
Net Foreign Currency Exchange Gain Loss — — — — — $6k $10k $27k — —
Net PPE Purchase And Sale — — — — — — $0 $0 ($54k) $0
Operating Gains Losses — — — — — — ($1.1m) $27k ($926k) $5.1m
Other Non Cash Items — — — — — — ($26k) ($14k) ($20k) ($34k)
Proceeds From Stock Option Exercised — — — — — $385k $0 $0 — —
Purchase Of Business — — — — — — $0 $0 ($410k) ($5k)
Purchase Of PPE — $2k $2k $2k $1k $1k $0 $0 ($54k) $0
Stock Based Compensation — — — — — — $14k $3k $264k $346k
Unrealized Gain Loss On Investment Securities — — — — — — $1.5m $1.0m ($167k) ($5k)
Profit or Loss ($2.5m) ($781k) $3.0m ($1.3m) ($3.0m) $435k ($1.3m) ($1.8m) ($1.0m) —
Cash flows from investing activities:
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities — $1k — — — — — — — —
Capital Expenditure — — — — — — — — ($54k) —
Net Investment Purchase And Sale — — — — — — $0 $0 ($14k) $777k
Purchase Of Investment — — — — — — $0 $0 ($14k) $0
Sale Of Investment — — — — — $0 — $0 $0 $777k
Net Other Investing Changes — — — — — — — — ($400k) ($250k)
Cash flows from financing activities:
Issuance Of Debt — — — — — — — $0 $0 $208k
Long Term Debt Issuance — — — — — — — $0 $0 $208k
Net Issuance Payments Of Debt — — — — — — $0 $0 ($13k) $208k
Net Long Term Debt Issuance — — — — — — — $0 $0 $208k
Net Short Term Debt Issuance — — — — — — $0 $0 ($13k) $0
Repayment Of Debt — — — — — — $0 $0 ($13k) $0
Short Term Debt Payments — — — — — — $0 $0 ($13k) $0
Common Stock Issuance — — — — — — $0 $0 $1.5m $0
Net Common Stock Issuance — — — — — — $0 $0 $1.5m $0
Losses from exchange rate differences on cash and cash equivalents — $2k ($4k) $3k $6k $6k $10k $27k ($15k) —
Exchange rate differences — — — — — — — $27k $14k ($35k)
Effect Of Exchange Rate Changes — — — — — — ($10k) ($27k) ($15k) $0
Decrease in cash and cash equivalents — — — $1.2m ($818k) ($656k) ($865k) ($666k) ($1.0m) ($295k)
Cash and cash equivalents at the beginning of the year — $3.3m $3.3m $4.5m $3.6m $3.0m $2.1m $1.4m $371k $76k
Change In Cash Supplemental As Reported — — — — — — ($865k) ($666k) ($1.0m) ($295k)

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.